Impact on survival of different treatments for myelodysplastic syndromes (MDS)

Abstract Therapies for myelodysplastic syndromes (MDS) often achieve hematological responses but their impact on overall survival has generally not been evaluated. The Duesseldorf MDS Registry allowed us to perform matched-pair analyses to assess a possible survival benefit of treatment with thalido...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2009-08, Vol.33 (8), p.1024-1028
Main Authors: Nachtkamp, Kathrin, Kündgen, Andrea, Strupp, Corinna, Giagounidis, Aristoteles, Kobbe, Guido, Gattermann, Norbert, Haas, Rainer, Germing, Ulrich
Format: Article
Language:English
Subjects:
Adult
Aged
Allogeneic transplantation
Antilymphocyte Serum - administration & dosage
Antithymocyte globulin
Cytarabine - administration & dosage
Disease-Free Survival
Enzyme Inhibitors - administration & dosage
Female
Germany
Hematology, Oncology and Palliative Medicine
Humans
Immunosuppressive Agents - administration & dosage
Induction chemotherapy
Low-dose Ara-C
Male
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - mortality
Myelodysplastic Syndromes - therapy
Prognosis
Registries
Retrospective Studies
Risk Factors
Stem Cell Transplantation
Survival Rate
Thalidomide
Thalidomide - administration & dosage
Transplantation, Homologous
Valproic acid
Valproic Acid - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Therapies for myelodysplastic syndromes (MDS) often achieve hematological responses but their impact on overall survival has generally not been evaluated. The Duesseldorf MDS Registry allowed us to perform matched-pair analyses to assess a possible survival benefit of treatment with thalidomide, valproic acid, low-dose Ara-C, antithymocyte globulin (ATG), induction chemotherapy, or allogeneic stem cell transplantation (allo-SCT). For all treatment modalities, lengthening of survival was restricted to certain subgroups of patients. With the exception of allo-SCT, MDS treatment was generally palliative. Recently, epigenetic treatment with demethylating agents proved to be the first therapy that can significantly prolong survival in patients with higher-risk MDS.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2008.12.019